Quarterly results reflect this momentum, with adjusted EPS of $2.50, compared to $1.81 a year ago, beating forecasts of $2.12. Revenue grew by 23% to reach $2.77bn. Instruments and accessories revenue reached $1.69bn, up 23%, supported by an approximately 16% increase in da Vinci procedures and a 39% jump for the Ion system.

In detail, procedures grew by 15% in the US and 20% internationally, while system sales reached $650.7m with 431 units installed, compared to 367 a year ago. Service revenue amounted to $433.7m. Furthermore, the group anticipates an adjusted gross margin between 67.5% and 68.5%, despite a negative impact of approximately 1% related to tariffs.